Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
Date:4/29/2011

NEW YORK, April 29, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease (the "Company"), today announced its results for the first quarter ended March 31, 2011.

At March 31, 2011, the Company had cash, cash equivalents and investment securities of $23.1 million, as compared to $28.5 million at December 31, 2010.  Subsequent to March 31, 2011, the Company received a $5.0 million milestone payment from its Japanese partner for Zerenex (ferric citrate), Japan Tobacco Inc. ("JT") and Torii Pharmaceutical Co., Ltd. ("Torii"), related to JT and Torii's commencement of a Phase 3 clinical program of ferric citrate in Japan.The net loss for the first quarter ended March 31, 2011, was $6.4 million, or $0.10 per share, compared to a net loss of $4.0 million, or $0.07 per share, for the comparable quarter in 2010, representing an increase in net loss of $2.4 million.  Other research and development expenses, for the first quarter ended March 31, 2011, increased by $2.1 million, as compared to the first quarter of 2010, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs.  The net loss for the first quarter ended March 31, 2011, included $0.6 million of non-cash compensation expense related to equity incentive grants.

Commenting on the quarter, Ron Bentsur, the Company's Chief Executive Officer, said, "During the first quarter, we continued to advance our compounds, perifosine and Zerenex, in Phase 3 development."  Ron Bentsur, continued, "We are focused on meeting the key clinical milestones that we have set out to achieve, while remaining operationally efficient with a well-controlled burn rate."

The Company will host an i
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
4. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 60 are not donor candidates for bone marrow transplantation. ... the elderly prone to life-threatening infection and other maladies, ... discovered a reason why. , "We have found the ... to maintain blood production over time in an old ... restored for rejuvenation therapies," said Emmanuelle Passegu, PhD, a ...
(Date:7/31/2014)... Chemists at Indiana University Bloomington have described the ... a development with potential value for the field ... and photovoltaic cells. , Their paper, "Anion-Induced Dimerization ... and 2D Self-Assembled Crystals," has been published online ... the Royal Society of Chemistry. It is the ...
(Date:7/31/2014)... Graphite Metallizing Corporation announces GRAPHALLOY® ... bearings are uniquely suited to prevent loss of lubrication ... the high temperatures . , Recently, a manufacturer ... engineers at Graphite Metallizing to overcome problems with movement ... operation, pans containing blocks of powder mixture are loaded ...
(Date:7/31/2014)... 2014 CollabRx, Inc. (NASDAQ: CLRX), a ... in oncology, today announced that it will hold an ... the Company's financial results for the first quarter of ... business in the current fiscal year. , The dial-in ... August 14, 2014, at 5 p.m. EDT (2 p.m. ...
Breaking Biology Technology:Key to aging immune system is discovered 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... Shandong, China, Feb. 13 /PRNewswire-Asia-FirstCall/ -- China,Biologic Products, ... the,"Company"), one of the leading plasma-based pharmaceutical companies ... that one of its R&D,projects, "High-Purity Human Albumin," ... China. , The National ...
... Prize, Draper Laboratory, in conjunction with the National Academy of Engineering ... learn about the impact engineers have had on our daily lives, ... been awarded "Engineering,s Nobel" since 1989. , ... Cambridge, ...
... 12 Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: ... and six-month periods ended December 31, 2008. Revenues for ... compared to $3.7 million for the second quarter of ... for the three months ended December 31, 2008 compared ...
Cached Biology Technology:China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan 2China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan 3New Educational Website Celebrates the Accomplishments of Engineers 2Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 2Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 3Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 4
(Date:7/31/2014)... photovoltaic effect in 1839, humankind has sought to further ... own purposes. In a new research report published in ... Journal , scientists may have uncovered a new ... on a naturally occurring combination of lipids that have ... time and across speciessuggests that this specific natural combination ...
(Date:7/31/2014)... Hibiscus flowers- they are an iconic symbol of ... in the landscape. Some, like Hawaii,s State Flower- ... Only a relatively few botanists and Hawaiian conservation ... and intriguing related group of plants known as ... Brother of Hibiscus species are in fact highly ...
(Date:7/31/2014)... that marine noise can affect animal movement and communication, ... Bristol and Exeter and the cole Pratique des Hautes ... noise stops embryonic development and increases larval mortality in ... Stylocheilus striatus used in this study) usually ... feed on toxic alga but this study, conducted in ...
Breaking Biology News(10 mins):Scientists shine bright new light on how living things capture energy from the sun 2Brother of Hibiscus is found alive and well on Maui 2Boat noise impacts development and survival of sea hares 2
... keep a protein "watchdog" on high alert to stop hereditary ... it on a leash of just the right length. , ... University's Susan M. Mendrysa has found that one of the ... the progression of intestinal tumors that arise from genetic predisposition. ...
... one of the best-studied organisms of the open sea, ... , Understanding krill is important because they are vital ... are vulnerable to fishing pressure and environmental change. In ... of the American Institute of Biological Sciences, Stephen Nicol ...
... CONRAD and the Biosyn Division of Cellegy Pharmaceuticals, Inc. ... develop Biosyn-patented microbicides for the prevention of HIV and ... three microbicides covered under the agreement are in various ... action. They include: Savvy, which is currently in ...
Cached Biology News:Loosen leash on cancer protein 'watchdog,' researchers say 2Loosen leash on cancer protein 'watchdog,' researchers say 3Loosen leash on cancer protein 'watchdog,' researchers say 4New licensing agreement to maximize AIDS drug development 2
...
BD BioCoat Laminin 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
... BD BioCoat Collagen I 60 mm Culture ... Culture Dishes, tissue-culture treated polystyrene with a uniform ... Coating : Collagen I ,Surface ... 21.3 cm2 ,Dim nominal : ...
Gelatin 100 mm Culture Dishes...
Biology Products: